NASDAQ:CCCC | Free Cash Flow | C4 Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$29.94M$64,000.00-$30.01M
2025-12-31-$22.15M$11,000.00-$22.16M
2025-03-31-$33.29M$0.00-$33.29M
2024-12-31-$17.93M-$4,000.00-$17.94M
2024-03-31-$18.12M$0.00-$18.12M
2023-12-31-$24.01M$157,000.00-$24.17M
2023-03-31-$33.13M$589,000.00-$33.71M
2022-12-31-$29.13M$1.49M-$30.62M
2022-03-31-$26.6M$172,000.00-$26.77M
2021-12-31-$25.67M$109,000.00-$25.78M
2021-03-31-$24.93M$421,000.00-$25.36M
2020-12-31-$21.59M$291,000.00-$21.88M
2020-03-31-$16.67M$184,000.00-$16.85M
2019-12-31-$10.3M-$73,000.00-$10.38M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$98.69M$607,000.00-$99.3M
2024-12-31-$65.16M$180,000.00-$65.34M
2023-12-31-$106.84M$1.71M-$108.55M
2022-12-31-$105.94M$5.5M-$111.44M
2021-12-31-$86.97M$1.28M-$88.24M
2020-12-31-$67.25M$650,000.00-$67.9M
2019-12-31$55.61M$1.35M$54.27M